Posts in: video (4)

ARCHIVE: Vision: What's the potential impact of exozymes?
investorvideoARCHIVE
ARCHIVE: Vision: What's the potential impact of exozymes?February 12, 2025
ARCHIVE: eXoZymes signifiy a sustainable paradigm shift in chemical production leveraging AI-engineered enzymes
investorvideoARCHIVE
ARCHIVE: eXoZymes signifiy a sustainable paradigm shift in chemical production leveraging AI-engineered enzymesFebruary 12, 2025
ARCHIVE: Looking at the rest of 2025 - part 4 of a fireside chat about Invizyne
heltzeninvestorvideoARCHIVE
ARCHIVE: Looking at the rest of 2025 - part 4 of a fireside chat about InvizyneFebruary 11, 2025
ARCHIVE: Go To Market Strategy - part 3 of a fireside chat about Invizyne
heltzeninvestorvideoARCHIVE
ARCHIVE: Go To Market Strategy - part 3 of a fireside chat about InvizyneJanuary 15, 2025
ARCHIVE: Using AI for Enzyme Engineering - Part 2 of a Fireside Chat About Invizyne
heltzeninvestorvideoARCHIVE
ARCHIVE: Using AI for Enzyme Engineering - Part 2 of a Fireside Chat About InvizyneJanuary 7, 2025
ARCHIVE: Looking back at 2024 - part 1 of a fireside chat about Invizyne
heltzeninvestorvideoARCHIVE
ARCHIVE: Looking back at 2024 - part 1 of a fireside chat about InvizyneDecember 31, 2024
ARCHIVE: Invizyne’s Nasdaq IPO Marks New Era of Biomanufacturing
press releaseinvestorvideoARCHIVE
ARCHIVE: Invizyne’s Nasdaq IPO Marks New Era of BiomanufacturingNovember 13, 2024
ARCHIVE: Commercializing Invizyne’s cell-free platform - fireside chat with Zachary Karl, PhD, VP of BizDev - and - Lou Basenese
investorvideoARCHIVE
ARCHIVE: Commercializing Invizyne’s cell-free platform - fireside chat with Zachary Karl, PhD, VP of BizDev - and - Lou BaseneseJuly 30, 2024
ARCHIVE: Invizyne IPO: interview with Dr. James J. Lalonde by MDB Capital President and Chief Market Strategist Lou Basenese
investorvideoARCHIVE
ARCHIVE: Invizyne IPO: interview with Dr. James J. Lalonde by MDB Capital President and Chief Market Strategist Lou BaseneseJuly 17, 2024
ARCHIVE: CEO Michael Heltzen and Co-Founder & VP of Research Dr. Tyler Korman present the Invizyne story and IPO opportunity to investors
investorvideoARCHIVE
ARCHIVE: CEO Michael Heltzen and Co-Founder & VP of Research Dr. Tyler Korman present the Invizyne story and IPO opportunity to investorsJune 18, 2024
Previous page
Page 4 of 5
Next page